Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Deutetrabenazine Therapy and CYP2D6 Genotype.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2019 May 1.

2.

Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.

Citrome L.

Expert Rev Neurother. 2018 Apr;18(4):323-332. doi: 10.1080/14737175.2018.1455504. Epub 2018 Apr 2. Review.

PMID:
29557243
4.

Deutetrabenazine in the treatment of tardive dyskinesia.

Niemann N, Jimenez-Shahed J.

Neurodegener Dis Manag. 2019 Apr;9(2):59-71. doi: 10.2217/nmt-2018-0042. Epub 2019 Jan 31.

PMID:
30702019
5.

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Niemann N, Jankovic J.

Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x. Review. Erratum in: Drugs. 2018 Mar 10;:. Dosage error in article text.

PMID:
29484607
6.

Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.

Dean M, Sung VW.

Drug Des Devel Ther. 2018 Feb 15;12:313-319. doi: 10.2147/DDDT.S138828. eCollection 2018. Review.

7.

Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.

Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.

J Clin Mov Disord. 2017 Mar 1;4:3. doi: 10.1186/s40734-017-0051-5. eCollection 2017.

8.

Dopamine depleters in the treatment of hyperkinetic movement disorders.

Jankovic J.

Expert Opin Pharmacother. 2016 Dec;17(18):2461-2470. Review.

PMID:
27819145
9.

Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.

Heo YA, Scott LJ.

Drugs. 2017 Nov;77(17):1857-1864. doi: 10.1007/s40265-017-0831-0. Review.

PMID:
29080203
10.

Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2017 Mar 23.

11.

VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.

Peckham AM, Nicewonder JA.

J Pharm Pract. 2018 Jan 1:897190018756512. doi: 10.1177/0897190018756512. [Epub ahead of print]

PMID:
29455579
12.

Deutetrabenazine for the treatment of Huntington's chorea.

Bashir H, Jankovic J.

Expert Rev Neurother. 2018 Aug;18(8):625-631. doi: 10.1080/14737175.2018.1500178. Epub 2018 Jul 17. Review.

PMID:
29996061
13.

Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.

Solmi M, Pigato G, Kane JM, Correll CU.

Drug Des Devel Ther. 2018 May 14;12:1215-1238. doi: 10.2147/DDDT.S133205. eCollection 2018. Review.

14.

Imipramine Therapy and CYP2D6 and CYP2C19 Genotype.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2017 Mar 23.

15.

Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.

Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, Duker A, Eberly S, Elmer L, Furr-Stimming E, Gudesblatt M, Hunter C, Jankovic J, Kostyk SK, Kumar R, Loy C, Mallonee W, Oakes D, Scott BL, Sung V, Goldstein J, Vaughan C, Testa CM; Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators.

JAMA Neurol. 2017 Aug 1;74(8):977-982. doi: 10.1001/jamaneurol.2017.1352.

16.

Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.

Paton DM.

Drugs Today (Barc). 2017 Feb;53(2):89-102. doi: 10.1358/dot.2017.53.2.2589164. Review.

PMID:
28387387
17.

VMAT2 Inhibitors in Neuropsychiatric Disorders.

Tarakad A, Jimenez-Shahed J.

CNS Drugs. 2018 Dec;32(12):1131-1144. doi: 10.1007/s40263-018-0580-y. Review.

PMID:
30306450
18.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.

JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.

19.

CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.

Rogers HL, Bhattaram A, Zineh I, Gobburu J, Mathis M, Laughren TP, Pacanowski M.

J Clin Psychiatry. 2012 Sep;73(9):1187-90. doi: 10.4088/JCP.11m07572.

PMID:
23059146
20.

46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE.

CNS Spectr. 2019 Feb;24(1):201. doi: 10.1017/S1092852919000397.

PMID:
30859974

Supplemental Content

Support Center